|
Palmetto
plus
Male Fluid Control ( with 23 medical references)An upgraded formulation to support the age-related changes common in men. Approximately 55% of men over 40, and 95% of men over 70 years of age manifest Benign Prostatic Hypertrophy (BPH). Early treatment will not only save millions of dollars in medical bills, but may prevent progression to life-threatening prostate cancer. Herbs and Nutrients that may Assist Saw palmetto (Serenoa repens) l-Glutamic acid l-Alanine l-Glycine Soya (Glycine max) Tomato (Lycopersicon esculentum) Zinc amino acid chelate Nettle root (Urtica dioica) Cholecalciferol Selenomethionine Dosage: 2-6 tablets daily Clinical Applications Benign Prostatic Hypertrophy (BPH) Prostatitis Urinary frequency and urgency Dysuria Nocturia Prevention of prostate cancer Scientific Research Benign Prostatic Hypertrophy Saw Palmetto reduces the activity of Epidermal Growth Factor (EGF) in the prostate by up to 66%. Excessive prostate EGF activity has been implicated in BPH. It also inhibits the conversion of testosterone to dihydrotestosterone (DHT) in the prostate and blocks the attachment of DHT to cellular binding sites, subsequently increasing its breakdown and excretion,,. DHT is activated testosterone, the most potent androgen, and is primarily responsible for prostate enlargement. This activity reduces the risk of prostate cancer,,. Saw Palmetto also acts directly on the enlarged prostate to reduce the pain and inflammation associated with this condition. Administration of 320 mg Serenoa extract per day alleviated the frequent, painful urination (dysuria) that occurs as a side effect of an enlarged prostate. In most cases of BPH being treated with Saw Palmetto, results will begin to become apparent after six to eight weeks, although maximum improvement normally does not occur for six months. Alanine, only when used in combination therapy with Glycine and Glutamic Acid, minimizes the symptoms of BPH,. Genistein from soy helps to prevent prostatic enlargement by inhibiting the activity of protein kinase C, an enzyme that stimulates the proliferation of benign cells. Lycopene from tomatoes reduces the risk of prostate cancer (primarily by interfering with the ability of Insulin-like Growth Factor-1 (IGF-1) to stimulate the growth of cancer cells),. Zinc alleviates BPH by inhibiting the 5-alpha reductase enzyme that is responsible for the conversion of testosterone to dihydrotestosterone,,,,. Nettle (Urtica dioica) helps to prevent, and is an effective treatment for existing, prostate cancer:
Vitamin D (especially the calcitriol and vitamin D3 forms) helps to prevent prostate cancer. The calcitriol levels of men with prostate cancer are usually lower than those of men who are free of it - especially in men aged 57 or over:
Selenium helps to prevent prostate enlargement through inhibiting cadmium-induced stimulation of the prostatic epithelium. Murray MT: Liposterolic extract of Serenoa repens in the treatment of benign prostatic hypertrophy. Phyto-Pharmacia Review 1988;1(8):1-4.2 Prostate. 37:77-83, 1999.3 New mechanism of saw palmetto found and revealed. Life Extension. 5(4):12, 1999.4 Bach, D., et al. Long-term drug treatment of benign prostatic hyperplasia - results of a prospective 3-year multicenter study using Sabal extract IDS 89. Phytomed. 3:105-111, 1996.5 Braeckman, J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res. 55:776-785, 1994.6 Champault, G., et al. Medical treatment of prostatic adenoma. Controlled trial. PA 109 vs placebo in 110 patients. Ann Urol. 18:407-410, 1984.7 Tasca, A., et al. Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo. Minerva Urol Nefrol. 37:87-91, 1985.8 New mechanism of saw palmetto found and revealed. Life Extension. 5(4):12, 1999.9 Murray, M. Saw palmetto extract: Nature’s answer to prostate enlargement.10 Damrau, F. Benign prostatic hypertrophy: amino acid therapy for symptomatic relief. Am J Geriatr. 10:426-430, 1962.11 Feinblatt, H. M., et al. Palliative treatment of benign prostatic hypertrophy: value of glycine, alanine, glutamic acid combination. J Maine Med Assoc. 46:99-102, 1958.12 Clinton, S. K. Lycopene: chemistry, biology and implications for human health and disease. Nutrition Reviews. 56:35-51, 1998.13 Pastori, M., et al. Lycopene in association with alpha-tocopherol inhibits at physiological concentrations proliferation of prostate carcinoma cells. Biochem Biophys Res Commun. 250:582-585, 1998.14 Bush, I. M., et al. Zinc and the prostate. Presented at the annual meeting of the American Medical Association. Chicago, 1974.15 Fahim, M., et al. Zinc treatment for the reduction of hyperplasia of the prostate. Federation Proceedings. 35:361, 1976.16 Leake, A., et al. Subcellular distribution of zinc in the benign and malignant human prostate: evidence for a direct zinc androgen interaction. Acta Endocrinol (Copenhagen). 105:281-288, 1984.17 Vasquez, A. Zinc treatment for reduction of hyperplasia of prostate. Townsend Letter for Doctors & Patients. April 1996:100.18 Wright, J. V. Treatment of benign prostate hypertrophy with zinc. Townsend Letter for Doctors & Patients. April 1996:82.19 Belaiche, P., et al. Clinical studies on the palliative treatment of prostatic adenoma with extract of Urtica root. Phytother Res. 5:267-269, 1991.20 Feldman, D., et al. Vitamin D and prostate cancer. Adv Exp Med Biol. 375:53-63, 1995.21 Wilczek, H. Importance of vitamin D in prostatic carcinoma. Cas Lek Cesk. 135:716-718, 1996.22 Webber, M. M. Selenium prevents the growth stimulatory effects of cadmium on human prostatic epithelium. Bicohem Biophy Res Commun. 127(3):871-877, 1985. |
|
|